Loading patent…
AssigneeNanjing Bioheng Biotech Co., Ltd.
InventorsYali ZHOU, Gong CHEN, Jie HUANG, Yingxiu TANG, Jiangtao REN
Estimating the term…
The present invention relates to an immunosuppressive molecule, comprising an immunosuppressive protein binding domain, a transmembrane domain, and a co-stimulatory domain and not comprising a primary signaling domain, wherein the immunosuppressive protein binding domain is selected from: an antibody targeting FasL, an antibody targeting IRP60, a ligand of IRP60 or a functional fragment thereof, an antibody targeting SIRPa, a ligand of SIRPa or a functional fragment thereof, wherein the immunosuppressive molecule can reduce immune rejection by cells of a subject. The present invention further relates to an engineered cell expressing the immunosuppressive molecule and a composition comprising the cell. Further provided in the present invention is a method for reducing immune rejection using the immunosuppressive molecule.
An immunosuppressive molecule, comprising an immunosuppressive protein binding domain, a transmembrane domain, and a co-stimulatory domain and not comprising a primary signaling domain, wherein the immunosuppressive protein binding domain is selected from:
6-8. (canceled)
(canceled)
(canceled)
15-17. (canceled)
(canceled)
(canceled)
(canceled)
26-30. (canceled)
(canceled)
36-37. (canceled)
Dependencies are inferred from the claim text.